Methylation of hypoxia-inducible factor 3 subunit alpha contributes to poor prognosis in lung adenocarcinoma.
Cell proliferation
DNMT1
HIF3A
Lung adenocarcinoma
Methylation
Journal
Journal of applied genetics
ISSN: 2190-3883
Titre abrégé: J Appl Genet
Pays: England
ID NLM: 9514582
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
06
2023
accepted:
29
08
2023
revised:
27
08
2023
medline:
10
11
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
ppublish
Résumé
Hypoxia-inducible factor 3 subunit alpha (HIF3A) has been implicated in various types of cancers, while its precise role in the lung adenocarcinoma remains unclear. Our study aimed to investigate the roles of HIF3A in lung adenocarcinoma and its regulation by DNA methylation. We utilized bioinformatic tools, including UALCAN and KMPlot, to analyze the relationship between HIF3A expression, DNA methylation, and patient survival rate in lung adenocarcinoma. We also used siRNA-mediated knockdown of HIF3A and DNA-methyltransferase 1 (DNMT1), as well as the treatment of DNA methylation inhibitor 5-Azacytidine, in A549 and H1299 lung adenocarcinoma cell lines. qPCR, MTT, and cell counting assays were performed to evaluate the mRNA expression and cell viability. The bioinformatic analysis revealed that HIF3A expression was downregulated and its methylation was upregulated in lung tumor tissues. Additionally, Kaplan-Meier analysis indicated a correlation between low HIF3A expression and patient poor survival rate. We found that DNMT1 regulated HIF3A methylation. Knockdown of HIF3A promoted cancer cell proliferation. These data suggest that downregulation of HIF3A promotes tumor cell proliferation, and support that HIF3A methylation may serve as a prognostic factor for lung adenocarcinoma.
Identifiants
pubmed: 37707680
doi: 10.1007/s13353-023-00784-6
pii: 10.1007/s13353-023-00784-6
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
HIF3A protein, human
0
Repressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
769-777Subventions
Organisme : Fuzhou Science and Technology Bureau
ID : AFZ2019S040076
Informations de copyright
© 2023. The Author(s), under exclusive licence to Institute of Plant Genetics Polish Academy of Sciences.
Références
Bjerre MT, Strand SH, Nørgaard M, Kristensen H, Rasmussen AK, Mortensen MM, Fredsøe J, Mouritzen P, Ulhøi B, Ørntoft T (2019) Aberrant DOCK2, GRASP, HIF3A and PKFP hypermethylation has potential as a prognostic biomarker for prostate cancer. Int J Mol Sci 20(5):1173
doi: 10.3390/ijms20051173
pubmed: 30866497
pmcid: 6429171
Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G (2008) DNA methylation markers and early recurrence in stage I lung cancer. New Engl J Med 358(11):1118–1128
doi: 10.1056/NEJMoa0706550
pubmed: 18337602
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, Varambally S (2017) UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19(8):649–658
doi: 10.1016/j.neo.2017.05.002
pubmed: 28732212
pmcid: 5516091
Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H (1997) The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26(1):14–23
doi: 10.1093/ije/26.1.14
pubmed: 9126499
Chen Q, Cao M, Ge H (2021) Knockdown of MALAT1 inhibits the progression of chronic periodontitis via targeting miR-769–5p/HIF3A axis. BioMed Res Int 2021:8899863
Dai Y, Xuan G, Yin M (2022) DUXAP8 Promotes LPS-induced cell injury in pulpitis by regulating miR-18b-5p/HIF3A. Int Dent J. https://doi.org/10.1016/j.identj.2022.11.011
Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21(35):5400–5413
doi: 10.1038/sj.onc.1205651
pubmed: 12154403
Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T (2000) DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 24(1):88–91
doi: 10.1038/71750
pubmed: 10615135
Hoang PH, Landi MT (2022) DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors. Cancers (Basel) 14(4):961
doi: 10.3390/cancers14040961
pubmed: 35205708
Janaszak-Jasiecka A, Bartoszewska S, Kochan K, Piotrowski A, Kalinowski L, Kamysz W, Ochocka RJ, Bartoszewski R, Collawn JF (2016) miR-429 regulates the transition between Hypoxia-Inducible Factor (HIF) 1A and HIF3A expression in human endothelial cells. Sci Rep 6(1):22775
doi: 10.1038/srep22775
pubmed: 26954587
pmcid: 4782134
Jaskiewicz M, Moszynska A, Serocki M, Króliczewski J, Bartoszewska S, Collawn JF, Bartoszewski R (2022) Hypoxia-inducible factor (HIF)-3a2 serves as an endothelial cell fate executor during chronic hypoxia. EXCLI J 21:454
pubmed: 35391921
pmcid: 8983852
Kulis M, Esteller M (2010) DNA methylation and cancer. Adv Genet 70:27–56
doi: 10.1016/B978-0-12-380866-0.60002-2
pubmed: 20920744
Lánczky A, Győrffy B (2021) Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res 23(7):e27633
doi: 10.2196/27633
pubmed: 34309564
pmcid: 8367126
Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18(10):2882–2895
doi: 10.1158/1078-0432.CCR-11-2090
pubmed: 22589488
Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P (2016) Risk factors for lung cancer worldwide. Eur Respir J 48(3):889–902
doi: 10.1183/13993003.00359-2016
pubmed: 27174888
Mansell T, Ponsonby A-L, Januar V, Novakovic B, Collier F, Burgner D, Vuillermin P, Ryan J, Saffery R, B. I. S. I. T. P. V. A.-L. P. J. C. K. A. M. T. R. S. S. R. D. B. T. D. K. J. P. Sly (2019) Early-life determinants of hypoxia-inducible factor 3A gene (HIF3A) methylation: a birth cohort study. Clin Epigenetics 11:1–12
doi: 10.1186/s13148-019-0687-0
Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1(1):49–52
doi: 10.1016/S1535-6108(02)00027-2
pubmed: 12086887
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594
Myers DJ, Wallen JM (2022) Lung adenocarcinoma. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing
Pathak R, Villaflor VM (2021) Histologic transformation in EGFR-mutant lung adenocarcinomas: mechanisms and therapeutic implications. Cancers (Basel) 13(18):4641
doi: 10.3390/cancers13184641
pubmed: 34572868
Shen J, Song R, Ye Y, Wu X, Chow W-H, Zhao H (2020) HIF3A DNA methylation, obesity and weight gain, and breast cancer risk among Mexican American women. Obes Res Clin Pract 14(6):548–553
doi: 10.1016/j.orcp.2020.10.001
pubmed: 33121895
Svedružić ŽM (2011) Dnmt1: structure and function. Prog Mol Biol Transl Sci 101:221–254
doi: 10.1016/B978-0-12-387685-0.00006-8
pubmed: 21507353
Wang D, Zhang S, Chen F (2018) High expression of PLOD1 drives tumorigenesis and affects clinical outcome in gastrointestinal carcinoma. Genet Test Mol Biomarkers 22(6):366–373
doi: 10.1089/gtmb.2018.0009
pubmed: 29723071
Yan Y, Zhang L, Zuo Y, Qian H, Liu C (2020) Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1/PD-L1 inhibitors. Arch Immunol Ther Exp (warsz) 68:1–15
doi: 10.1007/s00005-020-00601-6
Yang P (2009) Epidemiology of lung cancer prognosis: quantity and quality of life. Cancer Epidemiol 471:469–486
Yazdani B, Sirous H (2021) HIF3A: a potent prognostic biomarker in different kinds of cancer. https://doi.org/10.20944/preprints202104.0265.v1
Zöchbauer-Müller S, Minna JD, Gazdar AF (2002) Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7(5):451–457
doi: 10.1634/theoncologist.7-5-451
pubmed: 12401908